Zdrowie i gospodarka · 08/09/2016

FDA Clears Path for Abbreviated New Drug Applications for PREVACID IV

The FDA has determined that PREVACID IV (lansoprazole) intravenous injection, 30 mg/vial, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for the approval of abbreviated new drug applications for this product.